Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Current Assets
All assets expected to be converted to cash or used up within one year.
Opus Genetics, Inc.NASDAQ: IRD
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 39.0% from a year ago
Total current assets stood at $66.6M at the end of Q1 FY2026, up 39.0% from a year earlier and up 33.1% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.
Context
- Total current assets amounted to 99.7% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +39.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 50.04M USD
- Year-over-year change
- +36.7%
- 4-year CAGR
- +17.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.04M | +36.7% |
| FY2024 | 2024-12-31 | 36.61M | -32.1% |
| FY2023 | 2023-12-31 | 53.95M | +10.1% |
| FY2022 | 2022-12-31 | 48.99M | +87.9% |
| FY2021 | 2021-12-31 | 26.07M | — |
Total Current Assets vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total current assets of $66.6M is the 6th highest of the 10 companies compared; the peer median is $95.28M.
- Its year-over-year change of +39.0% is the 3rd highest of 10, against a peer median of -28.9%.
- Total current assets amounts to 99.7% of total assets for IRD, versus a peer median of 79.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $215.08M | -41.3% | -28.4% | 89.6% | |
| Mar 2026 | $188.3M | -14.1% | -10.8% | 93.9% | |
| Mar 2026 | $181.59M | -28.9% | -22.6% | 66.7% | |
| Mar 2026 | $133.09M | -14.1% | -12.2% | 99.6% | |
| Mar 2026 | $95.28M | +311.8% | -14.5% | 51.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.6M | +39.0% | +0.7% | 99.7% |
| Mar 2026 | $39.44M | -45.1% | -42.1% | 79.2% | |
| Mar 2026 | $35.81M | +56.6% | +0.2% | 99.1% | |
| Mar 2026 | $31.84M | -51.8% | -36.7% | 27.1% | |
| Mar 2026 | $6.98M | -51.3% | -32.1% | 23.5% | |
| Peer median (excluding IRD) | $95.28M | -28.9% | -22.6% | 79.2% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.